Data as of:
Price 02-03-26 16:00 ET,
Balance Sheet 2025-09-30,
Income Statement 2025-09-30,
Cash Flow 2025-09-30
Indicators
Dividend indicators
Value
Date
Pays Dividend
No
2-1-2026
Income indicators
Value
Date
EBITDA Positive
No
2-1-2026
Net Income Positive
No
2-1-2026
Avg CA Burn (Annual %)
-41.67%
2-1-2026
Avg CA Burn (Quarterly %)
1.79%
2-1-2026
Shares Outstanding Changes
Date
Shares Outstanding
Delta
2025-09-25
9,680,265
+4,925,000
2025-09-22
4,755,265
+74,265
2025-08-19
4,681,000
+1,317,000
Short Interest Changes
Latest short interest:
1,054,082 shares
(10.36% of float)
| Days to cover: 6.19
Date
Short Interest
Delta
Δ %
2026-02-03
1,054,082 shares
+0
+0.00%
2026-02-02
1,054,082 shares
+0
+0.00%
2026-01-30
1,054,082 shares
None
—
Interesting Volume Days
Volume/ratio use shares outstanding as of the event date (frozen).
Date
Volume
Shares Outstanding
Volume / Shares
Price
No interesting volume events
Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It also provides Saphyr and Stratys systems, which are sample-to-result solutions for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr and Stratys instruments, which are single-molecule imagers; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA; and Ionic purification system, which isolates and purifies nucleic acid molecules. In addition, the company offers Saphyr, Stratys, and Bionano compute servers; and VIA software, which offers one solution for analysis and interpretation of genomic data from microarray and sequencing data for cytogenetics and molecular genetics. Further, it provides testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.